Results 81 to 90 of about 14,264 (186)
Frontiers in EndocrinologyBackgroundUltra-long-acting insulin analogs [insulin degludec (IDeg) and insulin glargine 300 units/mL (IGla-300)] offer a longer duration of action with less risk of hypoglycemia compared to other long-acting insulins.
Eman N. Alhmoud +3 more
doaj +1 more source
Development and Purification of Polyclonal Antibody Against Glargine in Rabbits
Immunogenicity assessment requires the detection of anti - drug antibodies (ADAs) towards therapeutic insulin analogues like insulin glargine. The absence of well - characterized positive control antibodies is however a significant limitation in ...
{"name":"Sandeep Chakravarthi Kuppirala","email":"kuppirala.sandeep@gmail.com +1 more
core +2 more sources
Special aspects of concentrated insulins: basic characteristics and research findings
Сахарный диабет, 2019 The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e.
Tatiana Y. Demidova, Olga V. Balutina
doaj +1 more source
Exploratory Research in Clinical and Social PharmacyBackground: Treatment of type 1 diabetes requires insulin therapy, and various types of insulin can be used. Insulin glargine has been shown to provide effective glycemic control with reduced hypoglycemia.
Hiba Abdelmunim Suliman Elsheikh +7 more
doaj +1 more source
LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
, 2018 Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Yvette Lamb and Yahiya Syed are salaried employees of Adis/Springer, are responsible for the article content and ...
Yvette N Lamb (5031773) +3 more
core +1 more source
Insulin glargine use and breast cancer: a systematic review and meta-analysis
Electronic Physician, 2019 Background: Insulin is widely used in the treatment of diabetes. There is an increasing concern regarding the association between insulin glargine use and breast cancer.
Ibrahim Altedlawi Albalawi +1 more
doaj +1 more source
Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. [PDF]
, 2019 Insulin glargine is recombinant human insulin analog that is commonly used in patients with type 2 diabetes as well as those with type 1 diabetes. Pharmacokinetic and pharmacodynamics studies of insulin glargine had shown that it has an onset of action ...
Salameh, Obada +7 more
core +1 more source
, 2023 Background: In 2021, an insulin glargine biosimilar received an “interchangeable” designation, which, where allowed, enables pharmacists to automatically substitute these biosimilars when a reference product is prescribed.
Lim, Dooyoung +2 more
core +1 more source
, 2013 To describe treatment response and outcome in 15 cats with diabetic ketoacidosis (DKA) initially stabilized with glargine administered intramuscularly (IM) with or without subcutaneous (SC) glargine.Fifteen cats diagnosed with DKA were initially ...
Rand, Jacquie S. +3 more
core +1 more source